A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors

Summary

This is an open label, dose-escalation and expansion, single centre, phase Ia study . In this study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride liposome injection were studied in patients with advanced solid tumors, to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan hydrochloride liposome.

Timeline

Start

2014-09-09

Primary completion

2017-08-28

Completion

2017-08-28

Drugs

Indications